BIB - ProShares Ultra Nasdaq Biotechnology
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
55.62
-0.52 (-0.93%)
At close: 4:00PM EST
55.70 +0.08 (0.14%)
After hours: 4:57PM EST
Stock chart is not supported by your current browser
| Previous Close | 56.14 |
| Open | 56.11 |
| Bid | 52.30 x 900 |
| Ask | 58.10 x 1000 |
| Day's Range | 55.48 - 56.57 |
| 52 Week Range | 36.05 - 70.82 |
| Volume | 739,970 |
| Avg. Volume | 188,231 |
| Net Assets | 259.57M |
| NAV | 54.36 |
| PE Ratio (TTM) | N/A |
| Yield | 0.00% |
| YTD Return | 32.47% |
| Beta (3Y Monthly) | 2.93 |
| Expense Ratio (net) | 0.95% |
| Inception Date | 2010-04-06 |
Trade prices are not sourced from all markets
Investopedia•2 months agoTrump Foreshadows a Bleak Outlook for Biotech (IBB, BIB)
- Investor's Business Daily•4 months ago
Swing Trade In Biotech Sector Gave The Best Of Both Worlds
Stocks in the biotech sector pose a problem for a swing trade. We take profits quicker, so we need to avoid big losses. Biotech stocks make that difficult.
- Market Realist•5 months ago
Major Biotech ETFs Had Lackluster Performance in the Past Month
All three major biotechnology ETFs—the SPDR S&P Biotech ETF (XBI), the iShares NASDAQ Biotechnology Index (IBB), and the ProShares Ultra Nasdaq Biotechnology ETF (BIB)—have posted returns of ~1% in last month, starting on August 10. That compares unfavorably with the performance of the SPDR S&P 500 ETF (SPY), which returned ~1.7% in the same period.
- Investor's Business Daily•8 months ago
Biotech Funds Tacked On $76 Million This Week — Are They Recovering?
Biotech funds tacked on $76 million this week, adding to more than $500 million in net inflows over the past two weeks — a phenomenon the group hasn't seen in nine months.
